Skip to main content

Advertisement

SpringerLink
Log in

Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease

  • Nephrology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Over 8% of adults in the United States are estimated to have moderate (stages 3 and 4) chronic kidney disease (CKD), which is increasingly recognized as one of the independent predictors for cardiovascular (CV) disease and related mortality. Secondary hyperparathyroidism with elevated serum intact parathyroid hormone (iPTH) is associated with increased CV mortality in end-stage renal disease and this relationship is unclear in moderate CKD.

Methods

Medical records of 196 patients at Harry S. Truman Memorial Veterans Hospital with stages 3 and 4 CKD (glomerular filtration rate, GFR 16–59 ml/min/1.73 m2) who had iPTH levels determined from 4/2006 to 9/2007 were reviewed. CV event was defined as occurrence of any of the following during follow-up: myocardial infarction, stroke, coronary/carotid/peripheral artery revascularization, and death due to CV reasons.

Results

During median follow-up of 27.2 months, 48 patients had CV events, while 148 patients did not. iPTH was elevated (156.43 ± 107.49) for patients who had CV events compared with those without (109.12 ± 86.54, P = 0.003). Among the covariates studied in the multivariate analysis including history of vascular disease, 25-OH Vit D, corrected calcium, phosphorus levels, calcium–phosphorus product, and GFR, iPTH level was found to have a positive association with CV events during follow-up period (odds ratio = 1.3 for 50 pg/ml change in iPTH, 95% CI: 1.03–1.55, P = 0.02)). Cardiovascular disease history was the only other significant variable with estimated odds ratio of 5.9 (P = 0.002).

Conclusion

iPTH level in patients with stages 3 and 4 CKD is associated with increased incidence of cardiovascular events independent of calcium–phosphorous level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Coresh J et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038–2047

    Article  PubMed  CAS  Google Scholar 

  2. Sarnak MJ et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42(5):1050–1065

    Article  PubMed  CAS  Google Scholar 

  3. Daly C (2007) Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK consensus conference on early chronic kidney disease. Nephrol Dial Transplant 22(Suppl 9): ix19–ix25

    Google Scholar 

  4. Kimata N et al (2007) Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 11(3):340–348

    Article  PubMed  Google Scholar 

  5. Marco MP et al. (2003) Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl(85):S111–S114

  6. Young EW et al (2005) Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 67(3):1179–1187

    Article  PubMed  CAS  Google Scholar 

  7. Kovesdy CP et al (2008) Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73(11):1296–1302

    Article  PubMed  CAS  Google Scholar 

  8. De Boer IH et al (2002) The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 13(11):2762–2769

    Article  PubMed  Google Scholar 

  9. Bhuriya R et al (2009) Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the kidney early evaluation program (KEEP). Am J Kidney Dis 53(4 Suppl 4):S3–S10

    Article  PubMed  CAS  Google Scholar 

  10. Kamycheva E, Sundsfjord J, Jorde R (2004) Serum parathyroid hormone levels predict coronary heart disease: the Tromso study. Eur J Cardiovasc Prev Rehabil 11(1):69–74

    Article  PubMed  Google Scholar 

  11. Hagstrom E et al (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119(21):2765–2771

    Article  PubMed  Google Scholar 

  12. Pilz S, Tomaschitz A, Drechsler C et al (2010) Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 31(13):1591–1598 Epub 2010 May 2

    Article  PubMed  CAS  Google Scholar 

  13. Llach F (1995) Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 25(5):663–679

    Article  PubMed  CAS  Google Scholar 

  14. Schumock GT et al (2009) Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract 113(1):c54–c61

    Article  PubMed  CAS  Google Scholar 

  15. Jassal SK, Chonchol M, Mühlen DV et al (2010) Vitamin D, parathyroid hormone, and cardiovascular mortality in older adults: the Rancho Bernardo study. Am J Med 123(12):1114–1120

    Google Scholar 

  16. Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16:1788–1793

    Article  PubMed  CAS  Google Scholar 

  17. Covic A et al (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24(5):1506–1523

    Article  PubMed  Google Scholar 

  18. Usdin TB et al (1996) Distribution of parathyroid hormone-2 receptor messenger ribonucleic acid in rat. Endocrinology 137(10):4285–4297

    Article  PubMed  CAS  Google Scholar 

  19. Smogorzewski M (1995) PTH, chronic renal failure and myocardium. Miner Electrolyte Metab 21(1–3):55–62

    PubMed  CAS  Google Scholar 

  20. Ogino K, Burkhoff D, Bilezikian JP (1995) The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 136(7):3024–3030

    Article  PubMed  CAS  Google Scholar 

  21. Schluter KD, Piper HM (1992) Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 263(6 Pt 2):H1739–H1746

    PubMed  CAS  Google Scholar 

  22. Amann K et al (1994) A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4(10):1814–1819

    PubMed  CAS  Google Scholar 

  23. Schleiffer R, Pernot F, Jones R (1995) Endothelium is a target organ of parathyroid secretions in genetic hypertensive rats. Horm Metab Res 27(1):16–18

    Article  PubMed  CAS  Google Scholar 

  24. Noda M et al (1997) Increased expression of parathyroid hormone-related peptide gene in blood vessels of spontaneously hypertensive rats. Hypertension 30(5):1284–1288

    PubMed  CAS  Google Scholar 

  25. Ejerblad S, Eriksson I, Johansson H (1979) Uraemic arterial disease. An experimental study with special reference to the effect of parathyroidectomy. Scand J Urol Nephrol 13(2):161–169

    Article  PubMed  CAS  Google Scholar 

  26. Neves KR et al (2007) Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71(12):1262–1270

    Article  PubMed  CAS  Google Scholar 

  27. Rashid G et al (2007) Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 292(4):F1215–F1218

    Article  PubMed  CAS  Google Scholar 

  28. Perkovic V et al (2003) Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 26(1):27–33

    Article  PubMed  CAS  Google Scholar 

  29. Saleh FN et al (2003) Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24(22):2054–2060

    Article  PubMed  CAS  Google Scholar 

  30. Harnett JD et al (1988) Left ventricular hypertrophy in end-stage renal disease. Nephron 48(2):107–115

    Article  PubMed  CAS  Google Scholar 

  31. Piovesan A et al (1999) Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 50(3):321–328

    Article  CAS  Google Scholar 

  32. Hara S et al (1995) Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab 21(1–3):72–76

    PubMed  CAS  Google Scholar 

  33. Park CW et al (1999) Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33(1):73–81

    Article  PubMed  CAS  Google Scholar 

  34. Akmal M et al (1985) Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 75(3):1037–1044

    Article  PubMed  CAS  Google Scholar 

  35. Fadda GZ et al (1991) On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 87(1):255–261

    Article  PubMed  CAS  Google Scholar 

  36. Ogard CG et al (2005) Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 63(5):493–498

    Article  Google Scholar 

  37. Delfini E et al (2007) Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56(1):30–36

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

VISN 15 Veterans Administration Research award to A Chockalingam.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO, 65212, USA

    Anton Lishmanov

  2. Division of Nephrology, Harry S Truman Memorial Veterans’ Hospital, University of Missouri School of Medicine, Columbia, MO, 65212, USA

    Smrita Dorairajan, Kunal Chaudhary & Anand Chockalingam

  3. Division of Nephrology, Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO, 65212, USA

    Smrita Dorairajan & Kunal Chaudhary

  4. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO, 65212, USA

    Anand Chockalingam

  5. Department of Health Management and Informatics, University of Missouri School of Medicine, Columbia, MO, 65212, USA

    Youngju Pak

Authors
  1. Anton Lishmanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Smrita Dorairajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Youngju Pak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kunal Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anand Chockalingam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Smrita Dorairajan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lishmanov, A., Dorairajan, S., Pak, Y. et al. Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol 44, 541–547 (2012). https://doi.org/10.1007/s11255-010-9897-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-010-9897-2

Keywords

Search

Navigation